Gracell Biotechnologies to Report Third Quarter 2023 Financials on Monday, November 13, 2023

Rhea-AI Summary

Gracell Biotechnologies Inc. plans to release unaudited financial results for Q3 2023 and provide an update on recent developments on November 13, 2023. The company is a global clinical-stage biopharmaceutical company focused on developing cell therapies for cancer and autoimmune diseases. A live audio webcast and conference call will be held at 8:00 AM Eastern Time. Conference call and webcast details can be found on the company's website. A replay of the webcast will be available for 90 days.

SAN DIEGO and SUZHOU, China and SHANGHAI, China, Oct. 30, 2023 (GLOBE NEWSWIRE) -- Gracell Biotechnologies Inc. (NASDAQ: GRCL) (“Gracell”), a global clinical-stage biopharmaceutical company dedicated to developing innovative and highly efficacious cell therapies for the treatment of cancer and autoimmune diseases, today announced that it plans to release unaudited financial results for the third quarter ended September 30, 2023 and provide an update on recent developments prior to the open of the U.S. financial markets on Monday, November 13, 2023. The management team will host a live audio webcast and conference call at 8:00 AM Eastern Time.

Conference call and webcast details:
Monday, November 13, 2023 @ 8:00am ET
Investor domestic dial-in: (800) 715-9871
Investor international dial-in: +1 (646) 307-1963
Conference ID: 3201224

Live webcast link: https://ir.gracellbio.com/news-events/events-and-presentations

A replay of the webcast will be available on ir.gracellbio.com shortly after the conclusion of the event for 90 days.

About Gracell
Gracell Biotechnologies Inc. (“Gracell”) is a global clinical-stage biopharmaceutical company dedicated to discovering and developing breakthrough cell therapies for the treatment of cancers and autoimmune diseases. Leveraging its innovative FasTCAR and TruUCAR technology platforms and SMART CART™ technology module, Gracell is developing a rich clinical-stage pipeline of multiple autologous and allogeneic product candidates with the potential to overcome major industry challenges that persist with conventional CAR-T therapies, including lengthy manufacturing time, suboptimal cell quality, high therapy cost, and lack of effective CAR-T therapies for solid tumors and autoimmune diseases. The lead candidate BCMA/CD19 dual-targeting FasTCAR-T GC012F is currently being evaluated in clinical studies for the treatment of multiple myeloma, B-NHL and systemic lupus erythematosus (SLE). For more information on Gracell, please visit www.gracellbio.com. Follow @GracellBio on LinkedIn.

FAQ

When will Gracell Biotechnologies release its unaudited financial results for Q3 2023?

Gracell Biotechnologies plans to release its unaudited financial results for the third quarter ended September 30, 2023 on November 13, 2023.

What is the focus of Gracell Biotechnologies?

Gracell Biotechnologies is focused on developing innovative and highly efficacious cell therapies for the treatment of cancer and autoimmune diseases.

When will the live audio webcast and conference call be held?

The live audio webcast and conference call will be held on Monday, November 13, 2023 at 8:00 AM Eastern Time.

Where can I find the conference call and webcast details?

The conference call and webcast details can be found on the company's website.

How long will the webcast replay be available?

The webcast replay will be available on the company's website for 90 days.